# EDGAR Filing Document

**Accession Number:** 0002066836
**File Stem:** 0001062993-26-003128
**Filing Date:** 2026-6
**Character Count:** 8877
**Document Hash:** 89c95f16742a29b9dbd2ac1f03b5447a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-26-003128.hdr.sgml**: 20260609

**ACCESSION NUMBER**: 0001062993-26-003128

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260604

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260609

**DATE AS OF CHANGE**: 20260609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Conexeu Sciences Inc.
- **CENTRAL INDEX KEY:** 0002066836
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43283
- **FILM NUMBER:** 261076559

**BUSINESS ADDRESS:**
- **STREET 1:** 50 WEST LIBERTY STREET, SUITE 880
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89501
- **BUSINESS PHONE:** 604-315-4722

**MAIL ADDRESS:**
- **STREET 1:** 50 WEST LIBERTY STREET, SUITE 880
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89501

?xml version='1.0' encoding='ASCII'? Conexeu Sciences Inc.: Form 8-K - Filed by newsfilecorp.com

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**___________________________**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):  **<u>June 4, 2026</u>**

**<u>CONEXEU SCIENCES INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
|  **<u>Nevada</u>** |  **<u>001-43283</u>** |  **<u>33-4814282</u>** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **50 West Liberty Street, Suite 880, <u>Reno, Nevada, United States 89501</u>** (Address of principal executive offices) (ZIP Code)

Registrant's telephone number, including area code: **<u>(424) 333-5622</u>**

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbols** | **Name of each exchange on which registered** |
| Common Stock | CNXU | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

__________

------

**SECTION 3 - SECURITIES AND TRADING MARKETS**

**Item 3.02 Unregistered Sale of Equity Securities**

<u>Exercise of Common Stock Purchase Warrants and Warrant Exercise Incentive Program</u>

On June 4, 2026, Conexeu Sciences Inc. (the "**Registrant**" or the "**Company**") issued 416,667 shares of common stock (the "Warrant Shares"), upon the exercise of a like number of issued and outstanding common stock purchase warrants (the "**Warrants**"), for gross proceeds of approximately $166,667. The Company intends to use the proceeds for general working capital purposes.

The Warrants were subject to a warrant exercise incentive program (the "**Incentive Program**") adopted by the Company with effect from October 31, 2025, in order to encourage the early exercise of up to 5,733,226 of the Company's outstanding common stock purchase warrants (the "**Program Warrants**").

Pursuant to the Incentive Program, the Company has offered as an inducement to each Program Warrant holder who exercises a Program Warrant not later than 4:00 p.m. Pacific time on June 30, 2026, one additional transferable common stock purchase warrant (each, an "**Incentive Warrant**") for each Program Warrant exercised. Each Incentive Warrant will entitle the holder thereof to purchase one additional share of common stock of the Company (each, an "**Additional Warrant Share**") for a period of 36 months from the date of issuance of such Incentive Warrant, at an exercise price of $2.30 per Additional Warrant Share.

On June 4, 2026, 416,667 Incentive Warrants were issued to the one Warrant holder. Following exercise of the Warrants, a total of 410,338 Program Warrants remain outstanding.

Subsequent to the exercise of the Warrants, there were 26,658,330 shares of common stock outstanding.

The Warrant Shares and Incentive Warrants were issued upon exercise of the Warrants in transactions exempt from the registration requirements of the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"), in reliance on the exclusion from the registration requirements of the U.S. Securities Act provided by Rule 903(b) of Regulation S thereunder to the non-U.S. person.

The holder of the Program Warrants is among the selling security holders identified in the Registrant's registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the "**SEC**") pursuant to the U.S. Securities Act on November 28, 2025 (as amended, the "**Registration Statement**"), and declared effective by the SEC on May 11, 2026 (SEC File No. 333-291845). The Warrant Shares have been registered for resale pursuant to the Registration Statement.

The Additional Warrant Shares underlying the Incentive Warrants have not been and will not be registered under the U.S. Securities Act, or any state securities laws, and will only be issuable upon exercise of the Incentive Warrants in transactions that are exempt or excluded from the registration requirements of the U.S. Securities Act and applicable state securities laws.

------

<u>Exercise of Performance Warrants</u>

On June 8, 2026, the Company issued 100,000 shares of common stock (the "**Performance Warrant Shares**") at a price of $0.001 per share upon the exercise of a like number of issued and outstanding performance common stock purchase warrants (the "**Performance Warrants**"), for gross proceeds of $100. The Company relied upon the exemption from the registration requirements of the U.S. Securities Act provided by Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder for the issuance of such Performance Warrant Shares to the individual who is a U.S. person.

Subsequent to the exercise of the Performance Warrants, there were 26,758,330 shares of common stock outstanding.

**SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS**

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CONEXEU SCIENCES INC.** | **CONEXEU SCIENCES INC.** |
| **DATE: June 9, 2026** | By: | */s/ Stephen Inouye* |
|  |  | **Stephen Inouye** |
|  |  | **CFO, Secretary and Treasurer** |

---

------